Literature DB >> 30349571

Nitrosative stress indices in dogs with neurological form of canine distemper.

S Mahajan1, S Dey1, A Kumar1, P N Panigrahi2.   

Abstract

This is a prospective, controlled, randomized clinical study to evidence the role of nitrosative stress in development of overt neurological sign of canine distemper (CD). The enrollment of cases wasa made on basis of overt sign of CD (n=139) and the findings were compared with apparently healthy dogs (n=15). The CD specific immunoglobulins resulted in 94 confirmed positive cases. The nitric oxide (NO) and neuronal nitric oxide synthase (nNOS) concentration in cerebrospinal fluid (CSF) (18.08 ± 2.76, 415.84 ± 46.24, respectively) and plasma (32.68 ± 4.31, 321.31 ± 102.30, respectively) were significantly (P<0.05) elevated as compared to healthy control group. The concentration of neuron specific enolase (NSE) in CSF and plasma were also significantly (P<0.05) higher in dogs suffering from CD. The significant differences in other biochemical parameters like total protein, albumin and globulin were found in the CSF of dogs compared with healthy control. The author concludes that NO plays a role in pathophysiology of neurological form of CD and nNOS and NSE estimation in CSF and plasma could help in making early diagnosis of clinical cases.

Entities:  

Keywords:  Canine distemper; Cerebrospinal fluid; Neurological; Nitric oxide; Nitrosative stress

Year:  2018        PMID: 30349571      PMCID: PMC6184024     

Source DB:  PubMed          Journal:  Iran J Vet Res        ISSN: 2252-0589            Impact factor:   1.376


  17 in total

Review 1.  Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics.

Authors:  Hansotto Reiber
Journal:  Restor Neurol Neurosci       Date:  2003       Impact factor: 2.406

Review 2.  The function, composition and analysis of cerebrospinal fluid in companion animals: part II - analysis.

Authors:  Roberta Di Terlizzi; Simon R Platt
Journal:  Vet J       Date:  2008-02-21       Impact factor: 2.688

3.  Neuron-specific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children.

Authors:  Rachel Pardes Berger; Mary Clyde Pierce; Stephen R Wisniewski; P David Adelson; Robert S B Clark; Randy A Ruppel; Patrick M Kochanek
Journal:  Pediatrics       Date:  2002-02       Impact factor: 7.124

4.  Short-term prognostic value of serum neuron specific enolase and S100B in acute stroke patients.

Authors:  Sergio González-García; Alina González-Quevedo; Otman Fernández-Concepción; Marisol Peña-Sánchez; Caridad Menéndez-Saínz; Zenaida Hernández-Díaz; Marianela Arteche-Prior; Alejandro Pando-Cabrera; Carlos Fernández-Novales
Journal:  Clin Biochem       Date:  2012-07-20       Impact factor: 3.281

Review 5.  Nitric oxide and peroxynitrite in health and disease.

Authors:  Pál Pacher; Joseph S Beckman; Lucas Liaudet
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

Review 6.  Demyelination in canine distemper virus infection: a review.

Authors:  Marc Vandevelde; Andreas Zurbriggen
Journal:  Acta Neuropathol       Date:  2005-01-12       Impact factor: 17.088

7.  Cerebrospinal fluid total protein in patients with affective disorders.

Authors:  P J Pazzaglia; R M Post; D Rubinow; M A Kling; T S Huggins; T Sunderland
Journal:  Psychiatry Res       Date:  1995-08-28       Impact factor: 3.222

8.  Total protein, albumin quota, and electrophoretic patterns in cerebrospinal fluid of dogs with central nervous system disorders.

Authors:  D C Sorjonen
Journal:  Am J Vet Res       Date:  1987-02       Impact factor: 1.156

9.  Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis.

Authors:  K Rejdak; A Petzold; Z Stelmasiak; G Giovannoni
Journal:  Mult Scler       Date:  2007-09-24       Impact factor: 6.312

Review 10.  Aspects of canine distemper virus and measles virus encephalomyelitis.

Authors:  B A Summers; M J Appel
Journal:  Neuropathol Appl Neurobiol       Date:  1994-12       Impact factor: 8.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.